Sinopharm
1099.HK
#2278
Rank
NZ$11.09 B
Marketcap
$3.55
Share price
0.12%
Change (1 day)
-25.89%
Change (1 year)
The Sinopharm Group is a Chinese pharmaceutical company that researches, develops, produces, sells and markets pharmaceuticals and other health products.

Revenue for Sinopharm (1099.HK)

Revenue in 2023 (TTM): NZ$103.13 B

According to Sinopharm's latest financial reports the company's current revenue (TTM) is NZ$129.40 B. In 2022 the company made a revenue of NZ$129.40 B a decrease over the revenue in the year 2021 that were of NZ$132.17 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Sinopharm from 2006 to 2023

Annual revenue

Year Revenue Change
2023 (TTM) NZ$103.13 B-20.3%
2022 NZ$129.40 B-2.1%
2021NZ$132.17 B16.85%
2020NZ$113.11 B14.95%
2019NZ$98.40 B21.52%
2018NZ$80.97 B5.93%
2017NZ$76.44 B27.22%
2016NZ$60.08 B5.37%
2015NZ$57.01 B9.14%
2014NZ$52.24 B17.22%
2013NZ$44.56 B25.94%
2012NZ$35.38 B34.61%
2011NZ$26.29 B55.34%
2010NZ$16.92 B35.79%
2009NZ$12.46 B37.56%
2008NZ$9.06 B31.43%
2007NZ$6.89 B40.26%
2006NZ$4.91 B